Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease.
FGF21
NAFLD
NASH
Steatosis
Triglyceride
VLDL
Journal
Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
05
06
2020
revised:
16
07
2020
accepted:
08
08
2020
pubmed:
19
8
2020
medline:
28
1
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD), a form of chronic liver disease that occurs in individuals with no significant alcohol abuse, has become an increasing concern for global health. NAFLD is defined as the presence of lipid deposits in hepatocytes and it ranges from hepatic steatosis (fatty liver) to steatohepatitis. Emerging data from both preclinical studies and clinical trials suggest that the peroxisome proliferator-activated receptor (PPAR)β/δ plays an important role in the control of carbohydrate and lipid metabolism in liver, and its activation might hinder the progression of NAFLD. Here, we review the latest information on the effects of PPARβ/δ on NAFLD, including its capacity to reduce lipogenesis, to alleviate inflammation and endoplasmic reticulum stress, to ameliorate insulin resistance, and to attenuate liver injury. Because of these effects, activation of hepatic PPARβ/δ through synthetic or natural ligands provides a promising therapeutic option for the management of NAFLD.
Identifiants
pubmed: 32810487
pii: S0026-0495(20)30206-7
doi: 10.1016/j.metabol.2020.154342
pii:
doi:
Substances chimiques
PPAR delta
0
PPAR-beta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
154342Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflict of interest to declare.